Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GIM Biotech
Guangzhou, Guangdong, Chinagimbiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
GIM Biotech is a clinical-stage biotechnology company focused on the development of innovative gene therapies using advanced AAV vector technology. The company utilizes a proprietary platform for AAV vector screening and optimization to enhance delivery efficiency and tissue specificity. Its pipeline targets high-impact therapeutic areas including ophthalmology, hematology, and neurology. The lead candidate, GIM-001, is currently being evaluated for the treatment of wet age-related macular degeneration. GIM Biotech is headquartered in Guangzhou, China, and is supported by prominent venture capital investors.
- Therapeutic areas
- HematologyNeurologyOphthalmology
- Modalities
- Gene therapyBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on GIM Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GIM Biotech.